A most recent example of Schrodinger LLC’s collaborations with the start-up investor community is its December 2017 pact with Toronto-based MaRS Innovation, a non-profit, full-service commercialization accelerator funded in part by the Canadian government as well as 14 major Canadian universities and research institutes.Together, the two are backing a new private company, Bright Angel Therapeutics, with a mandate to tackle one of the most persistent – and underfunded – challenges in infectious disease:anti-fungal resistance.
The underlying condition is a heavy hitter. The US Centers for Disease Control & Prevention (CDC) describes invasive fungal disease...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?